Determining Swallow Outcomes in Head & Neck Lymphedema Subjects Receiving Early Intervention With Pneumatic Compression

NCT04335981 | Terminated FDA Device

• 1 other identifier: 8020
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of the study is to assess the effect early pneumatic compression (prior to confirming cancer-free status via PET or CT imaging) has on swallow outcomes, positron emission tomography (PET) measurements, function, and complication rate post-radiotherapy in subjects treated for oropharyngeal cancer.

Conditions

Head and Neck Lymphedema

Outcome Measures

Primary Outcomes (16)

• Swallow outcomes via modified barium swallow - Penetration-Aspiration Scale (PAS)

  PAS is an eight-point ordinal severity scale scoring the depth of airway invasion by the bolus, whether it is expelled from the airway as well as any patient reaction. It ranges from one (material does not enter the airway) to eight (material enters the airway, passes below the vocal folds, and no effort is made to eject). Min value = 1, Max value = 8, the lower the score the better.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via modified barium swallow - Pharyngeal Constriction Ratio (PCR)

  PCR is calculated by dividing the pharyngeal area (cm2) of the bolus hold frame (PAHOLD) by the maximum pharyngeal contraction frames (PAMAX). Min value = 0, Max value = 1. The lower the score, the better the outcome.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via modified barium swallow - Upper Esophageal Sphincter Opening (UESmax)

  UES measurements will include the: (1) maximum width of the UES opening as defined by the line between the anterior and posterior walls of the pharyngoesophageal segment at its narrowest area during its maximum opening in a lateral view, and (2) the maximum width of the UES opening as viewed anteriorly. Min value = 0, max value = 2. Greater the score, the better the outcome.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via modified barium swallow - Esophageal Bolus Transit Time (ETT)

  The time it takes the bolus to get through the cricopharyngeal muscle (where the esophageal phase is initiated) to the bottom of the esophagus (at the junction of the lower esophageal sphincter). Min value = 0, max value = 60. The lower the score, the better the outcome (seconds).

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via modified barium swallow - Normalized residue ratio scale (NRRS)

  Pharyngeal residue is the term used to describe material that remains in the pharynx post swallow (also called retention or stasis). The NRRS is calculated using ImageJ pixel area measures of residue in the valleculae. Min value = 0, max value = 1. The lower the score, the better the outcomes.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via modified barium swallow - Posterior Pharyngeal Wall Thickness (PPW)

  PPW is the thickness of the posterior pharyngeal wall in lateral view while holding a 1-ml liquid bolus in oral cavity prior to swallow (PPWhold). Min value = 0, max value = 30. The lower the score the better the outcomes (mm)

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Function - Stimulated Saliva Secretion Rate

  Stimulated Saliva Secretion Rate is the measure of total saliva collected in 3 minutes while chewing gum.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Swallow outcomes via patient reported outcome measure - Eating Assessment Tool (EAT-10) Questionnaire Score

  Min value = 0, max value = 4. The lower the score the better the outcome.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Patient Reported Function - Voice Handicap Index (VHI-10)

  A survey that quantifies the functional, physical, and emotional impacts of a voice disorder on a subject's quality of life. It captures the subject's subjective rating of a series of 10 questions. Min value = 0, max value = 40. The lower the score the better the outcomes.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Patient Reported Function - Functional Assessment of Cancer Therapy - Head and Neck (FACT HN)

  A survey which inquires on a series of concerns related to the head and neck region including oral comfort, breathing, voice, eating, appearance, tobacco, alcohol, and communication. The subject is asked to indicate how important each of the 39 listed concerns have been in the past 7 days. Min value = 0, max value = 148. The higher the score the better the quality of life.

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Nutrition - Weight

  Weight

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Nutrition - Body Mass Index (BMI)

  BMI

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Complications - Treatment Interruptions

  Number/days of treatment interruptions

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Complications - Hospitalizations

  Number/days of hospitalizations

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Complications - Pulmonary Infections

  Number/days of pulmonary infections

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

• Complications - Adverse Events

  Total number of adverse events

  Changes between Baseline, 6-Week Follow-Up, 12-Week Follow-Up, and 18-Week Follow-Up

Other Outcomes (2)

• PET Measurements - Epiglottic Thickness

  Changes between Baseline and 12-Week Follow-Up

• PET Measurements - Prevertebral Space

  Changes between Baseline and 12-Week Follow-Up

Study Arms (2)

FT-CC and Swallow Exercises

EXPERIMENTAL

Device: FT-CC and Swallow Exercises

Swallow Exercises

ACTIVE COMPARATOR

Other: Swallow Exercises

Interventions

FT-CC and Swallow Exercises DEVICE

Once daily treatment with FT Plus with investigational connectivity software and standard of care swallow exercises.

FT-CC and Swallow Exercises

Swallow Exercises OTHER

Standard of care swallow exercises.

Swallow Exercises

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• A previous diagnosis of oropharyngeal carcinoma requiring treatment with radiation therapy
• Diagnosis/evidence of lymphedema stage 1a or higher by clinical presentation based upon MD Anderson Cancer Center Head and Neck Lymphedema rating scale
• EAT-10 score \>4 at Baseline and Randomization Visits (prior to randomizing subject)
• The head and neck garments must fit appropriately (for patients with a tracheostomy, the fit will be assessed to ensure that the garments do not interfere with their tracheostomy)
• Ability to perform swallow exercises
• Willing and able to comply with the study protocol requirements and all study-related visit requirements
• Willing and able to provide informed consent prior to study participation

You may not qualify if:

• Synchronous treatment for cancer (may or may not have successfully complete prior cancer treatment)
• Other known causes of dysphagia such as previous radiation to the head and neck, or neuromuscular or neurodegenerative known to have a strong association with dysphagia (i.e., Parkinsons, ALS, MS, OPMD)
• Poorly controlled: kidney disease (glomerular filtration rate \< 30 mls per minute), hypoproteinemia, pulmonary hypertension, hypothyroidism or parathyroidism, cyclic edema, or Munchausen Syndrome (for which endocrinologist recommends against neck compression)
• Carotid sinus hypersensitivity syndrome
• Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness)
• Symptomatic bradycardia in the absence of a pacemaker
• Internal jugular venous thrombosis (within 3 months)
• Increased intracranial pressure or other contraindications to internal or external jugular venous compression
• Acute radiation dermatitis, unhealed surgical scar, unhealed or open wounds, surgical flap less than 6-8 weeks post-operative
• Facial or head and neck dermal metastasis
• Acute infection/inflammatory disease of the head and neck region (e.g., facial infection, parotid gland abscess, acute cellulitis, or other uncontrolled skin/untreated head and neck inflammatory skin disease)
• Any condition in which increased venous and lymphatic return is undesirable
• Heart failure (acute pulmonary edema, decompensated acute heart failure)
• Subject is pregnant or trying to become pregnant
• Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)

Sponsors & Collaborators

• Tactile Medical: lead

Study Sites (1)

University of California - Davis

Sacramento, California, 95817, United States

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2020
• First Posted: April 7, 2020
• Study Start: September 24, 2020
• Primary Completion: October 1, 2022
• Study Completion: October 1, 2022
• Last Updated: November 17, 2022

Record last verified: 2022-11

Locations

US (1)